CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 124 enrolled
Drug / intervention
Misoprostol vaginal insert 25 mcg +3 moredrug
Likely dose
Misoprostol vaginal insert 25 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00346840
NCT00346840Phase 2Completed

Controlled-Release Misoprostol Vaginal Insert in Parous Women for Labor Induction: Randomized Trial

Ferring Pharmaceuticals·interventional·Posted Jun 30, 2006·Updated Jun 18, 2012

In Brief

A Phase 2 clinical trial evaluating Misoprostol vaginal insert 25 mcg, Misoprostol vaginal insert 50 mcg, and 2 other interventions for Labor Induction and Cervical Ripening. Completed, enrolled 124 participants across 6 sites.

Detailed Summary

The primary objective of the study was assessment of the efficacy of four dose reservoirs (25 mcg, 50 mcg, 100 mcg, 200 mcg) of intravaginal controlled release misoprostol administered for up to 24 hours. Efficacy was measured in terms of time from insert placement to vaginal delivery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 30, 2006
Enrollment StartJun 1, 2003
Primary CompletionFeb 1, 2004
Study CompletionMar 1, 2004
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 20.0 years ago

Interventions

Misoprostol vaginal insert 25 mcgdrug

One hydrogel polymer vaginal insert for up to 24h

Misoprostol vaginal insert 50 mcgdrug

One hydrogel polymer vaginal insert for up to 24h

Misoprostol vaginal insert 100 mcgdrug

One hydrogel polymer vaginal insert for up to 24h

Misoprostol vaginal insert 200 mcgdrug

One hydrogel polymer vaginal insert for up to 24h